Eikon Therapeutics Presents Data on Clinical-Stage Programs at ASCO 2026

Eikon Therapeutics presented six abstracts featuring updated data from its lead clinical programs at the 2026 ASCO Annual Meeting in Chicago, with a focus on its TLR7/8 dual-agonist EIK1001 in NSCLC and advanced melanoma, updated data for its highly selective PARP1 inhibitor EIK1003, and early development progress for the WRN inhibitor candidate EIK1005.; The company highlighted that its EIK1001 combination data in first-line NSCLC show encouraging response rates and durability, while EIK1003 data include updated results from monotherapy and combination cohorts in platinum‑resistant ovarian and breast cancer settings.; EIK1005 data at the meeting include first‑in‑human pharmacokinetic, pharmacodynamic, and trial‑in‑progress information for the novel WRN helicase inhibitor in healthy volunteers and patients with advanced solid tumors, including MSI‑H or dMMR tumors.